Chapter 20
Other Respiratory Disorders
Hipertensão Pulmonar: Classificação e Patogênese
Pulmonary hypertension, or PH, denotes the resting mean pulmonary arterial pressure of 25 mm Hg or higher.
Pulmonary hypertension can be classified into ...
Tratamento para hipertensão arterial pulmonar: inibidores da fosfodiesterase
Phosphodiesterase inhibitors treat pulmonary arterial hypertension or PAH by inhibiting the activity of the phosphodiesterase enzyme.
Phosphodiesterase 5 ...
Tratamento para hipertensão arterial pulmonar: antagonistas do receptor de endotelina
Endothelin receptor antagonists or ERAs counteract the effects of endothelins, or ETs, to treat pulmonary arterial hypertension or PAH.
ETs are produced ...
Tratamento para hipertensão arterial pulmonar: agonistas do receptor de prostaciclina
Prostacyclin receptor agonists are vital in managing pulmonary arterial hypertension.
They mimic prostaglandin I2 and bind to its receptor, IPR, on ...
Tratamento para hipertensão arterial pulmonar: inibidores do receptor de tirosina quinase e bloqueadores dos canais de cálcio
Receptor tyrosine kinase inhibitors or TKIs and calcium channel blockers or CCBs are used for pulmonary arterial hypertension or PAH treatment.
TKIs like ...
Tratamento da Hipertensão Arterial Pulmonar: Oxigenoterapia para Insuficiência Respiratória
Oxygen therapy can enhance the quality of life of patients with pulmonary arterial hypertension or PAH who experience hypoxemia or low oxygen levels. This ...
Fibrose cística: patogênese
Cystic fibrosis, or CF, is an autosomal recessive disorder resulting from mutations in the cystic fibrosis transmembrane conductance regulator or CFTR ...
Fibrose cística: tratamento
Cystic fibrosis, or CF, is an autosomal genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator or CFTR gene.
CF ...
Copyright © 2025 MyJoVE Corporation. Todos os direitos reservados